Biotech | March 10, 2022
Pfizer initiates Phase2/3 study of Paxlovid in pediatric participants
Paxlovid is the first oral therapy specifically designed to combat Covid-19 to be evaluated in a pediatric clinical study
Paxlovid is the first oral therapy specifically designed to combat Covid-19 to be evaluated in a pediatric clinical study
Breakthrough formulation helps reduce the risk of exposure using a non-hazardous formulation and leakproof format during transport and processing
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
As an initial remote monitoring diagnostic approach, Philips BioTel Heart MCOT detected 4.6 times more patients with atrial fibrillation compared to implantable loop recorder alone
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
Routine tests undertaken by women dropped by 35% in 2020
Under this year’s theme of ‘Kidney Health For All’, ISN along with AstraZeneca aims to generate large scale awareness and educate people about ways to improve kidney health
This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development
Subscribe To Our Newsletter & Stay Updated
